PaperThe concentration of tissue plasminogen activator and urokinase in plasma and tissues of patients with ovarian and uterine tumors
References (20)
- et al.
Plasminogen activators, tissue degradation and cancer
Advances in Cancer Res.
(1985) - et al.
The urokinase type of plasminogen activator in cancer of digestive tracts
Thromb. Res.
(1988) - et al.
Characterization of various antibodies against tissue plasminogen activator using highly sensitive enzyme immunoassay
Thromb. Res.
(1986) - et al.
Determination of urokinase in the urine of healthy volunteers and patients with renal disease
Thromb. Res.
(1986) - et al.
Relationship between age and plasma t-PA, PA inhibitor and PA activity
Thromb. Res.
(1987) - et al.
The Mr 17,500 region of the A chain of urokinase is required for interaction with a specific receptor in A431 cells
Biochim. Biophys. Acta
(1986) - et al.
Plasminogen activator activity and composition in human breast cancer
Cancer Res.
(1982) - et al.
Plasminogen activator secretion of human tumors in short-term organ culture, including a comparison of primary and metastatic colon tumors
Cancer Res.
(1983) - et al.
Plasminogen activator content of neoplastic and benign human prostate tissues; fibrin augmentation of an activator activity
Int. J. Cancer
(1981) Fibrinolysis: An overview
There are more references available in the full text version of this article.
Cited by (52)
Plasmin triggers a switch-like decrease in thrombospondin-dependent activation of TGF-β1
2012, Biophysical JournalSteady states and dynamics of urokinase-mediated plasmin activation in silico and in vitro
2011, Biophysical JournalCitation Excerpt :The PLS concentrations that show bistability in simulations (0.03–0.05 μM) would be reasonable in vivo because the total pool of PLS plus PLG was previously measured to be 0.5–2 μM (37–40). The level of scUPA needed to cause a state transition in simulations (0.7μM) is significantly above the empirical range of 0.1 nM to 0.1 μM measured for total urokinase (tcUPA plus scUPA) (41–44). Many factors could be responsible for the difference between simulated and measured urokinase values, including the greater activity of tcUPA compared with scUPA, different tissue types, and different measurement methods.
Tumor-associated proteolytic factors uPA and PAI-1 in endometrial carcinoma
1997, Gynecologic OncologyInvolvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview
2014, Medicinal Research Reviews
Copyright © 1990 Published by Elsevier Ireland Ltd.